BRPI0915273A2 - Derivado tricíclico inovador ou seus sais farmaceuticamente aceitáveis, seu método de preparação e composição farmacêutica que os contém. - Google Patents
Derivado tricíclico inovador ou seus sais farmaceuticamente aceitáveis, seu método de preparação e composição farmacêutica que os contém.Info
- Publication number
- BRPI0915273A2 BRPI0915273A2 BRPI0915273-3A BRPI0915273A BRPI0915273A2 BR PI0915273 A2 BRPI0915273 A2 BR PI0915273A2 BR PI0915273 A BRPI0915273 A BR PI0915273A BR PI0915273 A2 BRPI0915273 A2 BR PI0915273A2
- Authority
- BR
- Brazil
- Prior art keywords
- innovative
- preparation
- pharmaceutically acceptable
- pharmaceutical composition
- acceptable salts
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20080111808 | 2008-11-11 | ||
| KR10-2008-0111808 | 2008-11-11 | ||
| PCT/KR2009/006618 WO2010056038A2 (ko) | 2008-11-11 | 2009-11-11 | 신규한 트리시클릭 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 약학적 조성물 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI0915273A2 true BRPI0915273A2 (pt) | 2015-08-04 |
| BRPI0915273B1 BRPI0915273B1 (pt) | 2021-08-03 |
Family
ID=42170514
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0915273-3A BRPI0915273B1 (pt) | 2008-11-11 | 2009-11-11 | Derivado tricíclico ou seus sais farmaceuticamente aceitáveis e seus métodos de preparação |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8815891B2 (pt) |
| EP (1) | EP2364983B1 (pt) |
| JP (1) | JP5403709B2 (pt) |
| KR (1) | KR100968175B1 (pt) |
| CN (1) | CN102245612B (pt) |
| AU (1) | AU2009314760B2 (pt) |
| BR (1) | BRPI0915273B1 (pt) |
| CA (1) | CA2743257C (pt) |
| DK (1) | DK2364983T3 (pt) |
| ES (1) | ES2443127T3 (pt) |
| MX (1) | MX2011004957A (pt) |
| PL (1) | PL2364983T3 (pt) |
| PT (1) | PT2364983E (pt) |
| RU (1) | RU2470934C1 (pt) |
| WO (1) | WO2010056038A2 (pt) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101827444B1 (ko) * | 2012-02-01 | 2018-02-08 | 제일약품주식회사 | 트리사이클로 유도체 화합물의 신규한 결정형 산부가염 또는 이의 수화물 및 이의 제조방법 |
| WO2015089842A1 (en) * | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Novel tricyclic calcium sensing receptor antagonists for the treatment of osteoporosis |
| WO2015173133A1 (en) | 2014-05-12 | 2015-11-19 | Chiesi Farmaceutici S.P.A. | Formulations and methods of treating alzheimer's disease and other proteinopathies by combination therapy |
| TW201636329A (zh) | 2015-02-02 | 2016-10-16 | 佛瑪治療公司 | 作為ｈｄａｃ抑制劑之雙環［４，６，０］異羥肟酸 |
| PL3292116T3 (pl) | 2015-02-02 | 2022-02-21 | Valo Health, Inc. | 3-arylo-4-amidobicykliczne kwasy [4,5,0]hydroksamowe jako inhibitory hdac |
| MX375707B (es) * | 2015-06-09 | 2025-03-06 | Onconic Therapeutics Inc | Compuesto derivativo triciclico, metodo para prepararlo y composicion farmaceutica que comprende el mismo. |
| KR101775356B1 (ko) | 2015-07-06 | 2017-09-06 | 재단법인 아산사회복지재단 | Parp 및 탄키라제 동시 저해제에 대한 감수성 결정 방법 |
| RU2602503C1 (ru) * | 2015-09-23 | 2016-11-20 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная химико-фармацевтическая академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО СПХФА) | Трициклические соединения, обладающие противобактериальной активностью, способ их получения и содержащее их фармацевтическое средство |
| EP3472131B1 (en) | 2016-06-17 | 2020-02-19 | Forma Therapeutics, Inc. | 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors |
| KR20180062804A (ko) * | 2016-12-01 | 2018-06-11 | 사회복지법인 삼성생명공익재단 | 트리시클릭 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 허혈성 급성 신손상 예방 또는 치료용 약학적 조성물 |
| JP7091336B2 (ja) * | 2016-12-22 | 2022-06-27 | グローバル ブラッド セラピューティクス インコーポレイテッド | ヒストンメチルトランスフェラーゼ阻害剤 |
| WO2018226998A1 (en) | 2017-06-09 | 2018-12-13 | Global Blood Therapeutics, Inc. | Azaindole compounds as histone methyltransferase inhibitors |
| CA3095371A1 (en) * | 2018-04-13 | 2019-10-17 | Cancer Research Technology Limited | Bcl6 inhibitors |
| WO2020072675A1 (en) | 2018-10-02 | 2020-04-09 | Northwestern University | Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2c (5-ht2c) |
| US20220110936A1 (en) * | 2019-02-02 | 2022-04-14 | Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences | Pharmaceutical composition for treatment of neurodegenerative diseases or diseases caused by abnormality of rna binding protein and applications thereof |
| MX2022001200A (es) * | 2019-07-29 | 2022-02-21 | Jeil Pharmaceutical Co Ltd | Metodo para el tratamiento de accidente cerebrovascular usando un derivado triciclico. |
| KR20210014024A (ko) | 2019-07-29 | 2021-02-08 | 제일약품주식회사 | 트리사이클릭 유도체를 이용한 뇌졸중의 치료 방법 |
| GB201914860D0 (en) | 2019-10-14 | 2019-11-27 | Cancer Research Tech Ltd | Inhibitor compounds |
| KR20220149268A (ko) * | 2021-04-30 | 2022-11-08 | 주식회사 온코크로스 | 트리사이클로 유도체 화합물을 포함하는 대사질환 예방 또는 치료용 조성물 |
| CN115554303B (zh) * | 2021-09-18 | 2024-07-09 | 上海科技大学 | 一种三环类化合物、其制备方法及其应用 |
| WO2023061406A1 (zh) * | 2021-10-12 | 2023-04-20 | 微境生物医药科技(上海)有限公司 | 含三并环结构的parp抑制剂、及其制备方法和医药用途 |
| AU2023235233A1 (en) | 2022-03-14 | 2024-09-12 | Slap Pharmaceuticals Llc | Multicyclic compounds |
| WO2024258904A1 (en) * | 2023-06-13 | 2024-12-19 | University Of Georgia Research Foundation, Inc. | Tetrahydroacridinone analogues for treatment and prevention of malaria |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5391554A (en) * | 1992-09-09 | 1995-02-21 | Warner-Lambert Company | Dihydro- and tetrahydronaphthyridines |
| US20020022636A1 (en) * | 1997-09-03 | 2002-02-21 | Jia-He Li | Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity |
| US6197785B1 (en) * | 1997-09-03 | 2001-03-06 | Guilford Pharmaceuticals Inc. | Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity |
| JP2000239273A (ja) * | 1999-02-16 | 2000-09-05 | Nippon Kayaku Co Ltd | ４−アミノ−５，６，７，８−テトラヒドロ〔１，６〕ナフチリジン誘導体の新規製造法 |
| TWI262919B (en) | 1999-10-25 | 2006-10-01 | Yamanouchi Pharma Co Ltd | Naphthyridine derivative |
| AUPS137402A0 (en) * | 2002-03-26 | 2002-05-09 | Fujisawa Pharmaceutical Co., Ltd. | Novel tricyclic compounds |
| ATE411996T1 (de) * | 2002-09-30 | 2008-11-15 | Bayer Healthcare Ag | Kondensierte azolpyrimidinderivate |
| DE102004028973A1 (de) * | 2004-06-16 | 2006-01-05 | Sanofi-Aventis Deutschland Gmbh | Substituierte Tetrahydro-2H-isochinolin-1-on-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament |
| EP2468748B1 (en) * | 2006-02-15 | 2016-05-25 | AbbVie Inc. | Pyrazoloquinolones are potent parp inhibitors |
| BRPI0719123A2 (pt) * | 2006-09-01 | 2013-12-17 | Cylene Pharmaceuticals Inc | Moduladores de serina-treonina proteína cinase e parp |
| KR101179753B1 (ko) | 2007-11-06 | 2012-09-04 | 제일약품주식회사 | 신규한 트리시클릭 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 포함하는 약학조성물 |
-
2009
- 2009-11-11 AU AU2009314760A patent/AU2009314760B2/en active Active
- 2009-11-11 CA CA2743257A patent/CA2743257C/en active Active
- 2009-11-11 RU RU2011123799/04A patent/RU2470934C1/ru active
- 2009-11-11 EP EP09826270.2A patent/EP2364983B1/en active Active
- 2009-11-11 DK DK09826270.2T patent/DK2364983T3/da active
- 2009-11-11 CN CN200980150285.4A patent/CN102245612B/zh active Active
- 2009-11-11 MX MX2011004957A patent/MX2011004957A/es active IP Right Grant
- 2009-11-11 KR KR1020090108588A patent/KR100968175B1/ko active Active
- 2009-11-11 PT PT98262702T patent/PT2364983E/pt unknown
- 2009-11-11 BR BRPI0915273-3A patent/BRPI0915273B1/pt active IP Right Grant
- 2009-11-11 JP JP2011536240A patent/JP5403709B2/ja active Active
- 2009-11-11 US US13/128,030 patent/US8815891B2/en active Active
- 2009-11-11 PL PL09826270T patent/PL2364983T3/pl unknown
- 2009-11-11 ES ES09826270.2T patent/ES2443127T3/es active Active
- 2009-11-11 WO PCT/KR2009/006618 patent/WO2010056038A2/ko not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| DK2364983T3 (da) | 2013-12-09 |
| PL2364983T3 (pl) | 2014-04-30 |
| CN102245612A (zh) | 2011-11-16 |
| EP2364983B1 (en) | 2013-10-23 |
| EP2364983A4 (en) | 2012-05-09 |
| WO2010056038A2 (ko) | 2010-05-20 |
| CA2743257C (en) | 2014-02-11 |
| EP2364983A2 (en) | 2011-09-14 |
| CA2743257A1 (en) | 2010-05-20 |
| JP2012508273A (ja) | 2012-04-05 |
| MX2011004957A (es) | 2011-08-12 |
| JP5403709B2 (ja) | 2014-01-29 |
| ES2443127T3 (es) | 2014-02-17 |
| BRPI0915273B1 (pt) | 2021-08-03 |
| KR100968175B1 (ko) | 2010-07-07 |
| PT2364983E (pt) | 2014-01-07 |
| CN102245612B (zh) | 2014-11-05 |
| AU2009314760B2 (en) | 2011-11-10 |
| US20110218193A1 (en) | 2011-09-08 |
| WO2010056038A3 (ko) | 2010-09-16 |
| HK1164292A1 (en) | 2012-09-21 |
| KR20100053468A (ko) | 2010-05-20 |
| RU2470934C1 (ru) | 2012-12-27 |
| AU2009314760A1 (en) | 2011-06-30 |
| US8815891B2 (en) | 2014-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0915273A2 (pt) | Derivado tricíclico inovador ou seus sais farmaceuticamente aceitáveis, seu método de preparação e composição farmacêutica que os contém. | |
| BRPI0918841A2 (pt) | derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol, seus cristais e composições farmacêuticas | |
| BR112012001915A2 (pt) | derivado de análogo de glp-1 ou seus sais farmacêuticos e seu uso. | |
| BRPI1009324A2 (pt) | compostos e/ou farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e respectivos usos | |
| BRPI1007173A2 (pt) | composição farmacêutica compreendendo ácido sórbico e benzóico e seus derivados que melhora a atividade de um neurofármaco, e seu uso, formulação farmacêutica e método de mitigação de um ou mais sintomas de um distúrbio neuropsiquiátrico | |
| CL2014000732A1 (es) | Compuestos derivados heterociclicos para su uso en la prevencion o tratamiento de una infeccion por flavivirus; metodo para su preparacion; y composicion farmaceutica que los comprende. | |
| BRPI0908021A2 (pt) | Composto, composição farmacêutica, e, usos do composto ou da composição farmacêutica | |
| BRPI0811034A2 (pt) | Derivados de aminodi-hidrotiazina substituídos com um grupo cíclico e seus usos e composições farmacêuticas | |
| BRPI0924427A2 (pt) | composição farmacêutica de liberação controlada, seu processo de preparação e uso da mesma | |
| DK2282994T3 (da) | 3-aminocarbazolforbindelse, farmaceutisk sammensætning indeholdende forbindelsen samt fremstillingsmetode derfor | |
| BRPI1008045A2 (pt) | derivados de aminotetralina, composições farmacêuticas contendo-os, e seu uso em terapia | |
| IL250740B (en) | Piperazine-2,5-dione derivatives, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments | |
| BR112013011949A2 (pt) | "indóis, composição farmacêutica que os compreende, seus processos de preparação e uso dos ditos indóis" | |
| BRPI0907591A2 (pt) | Compostos e composição farmacêutica como moduladores de atividade de gpr119, método in vitro para modulação da atividade de gpr119 e usos do referido composto, seus sais farmaceuticamente aceitáveis ou suas composições farmacêuticas. | |
| BRPI0806686A2 (pt) | Compostos e seus usos, métodos de tratamento ou prevenção, composições farmacêuticas e composto e solvato cristalinos | |
| BRPI0912356A2 (pt) | compostos moduladores de sirtuína, composição farmacêutica compreendendo os mesmos e seu uso | |
| UY31673A1 (es) | "derivados heterocíclicos de urea y métodos de uso de los mismos-211" | |
| BRPI0815606A2 (pt) | Derivados de 6-triazol piridazina - sulfanil benzotiazol e benzimidazol, o respectivo processo de preparo, a respectiva aplicação a título de medicamentos, composições farmacêuticas e utilização, notadamente como inibidores de met. | |
| BRPI0910557A2 (pt) | composições farmacêuticas de paclitaxel, análogos de paclitaxel ou conjugados de paclitaxel e métodos relacionados de preparação e uso. | |
| BRPI1009481A2 (pt) | compostos de 2-acetamido-5-aril-1,2,4-triazolonas substituídas, seu processo de preparação, seu uso e medicamento compreendendo os mesmos | |
| BR112015011036A2 (pt) | derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais | |
| BRPI0821115A2 (pt) | Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto | |
| BR112012003842A2 (pt) | composição farmacêutica, método de formulação e uso da mesma | |
| BRPI0815894A2 (pt) | Composição farmacêutica, uso da mesma, e, sais farmaceuticamente aceitáveis de um composto. | |
| BRPI0809346A2 (pt) | Compostos derivados substituídos de imidazopiridina e composição farmacêutica contendo os mesmos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/11/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |